Last updated: May 1, 2026
OMNIPAQUE 300: Who Supplies It and What They Provide
OMNIPAQUE 300 (iopamidol injection, 300 mg iodine/mL) is supplied in the U.S. market by GE HealthCare under the Omnipaque brand for multiple pack formats (including vial sizes). Distribution typically runs through wholesalers and specialty channels rather than a single “raw-material supplier” contract model.
Who supplies OMNIPAQUE 300 in the U.S.?
- Brand holder / manufacturer: GE HealthCare (Omnipaque brand; iopamidol injection, 300 mg iodine/mL).
- Market distribution: pharmaceutical wholesalers (U.S.) and specialty distributors for radiology and hospital procurement.
What product formats are supplied?
OMNIPAQUE 300 is supplied as an injectable radiographic contrast product (iopamidol, 300 mg iodine/mL) in multiple vial presentations used in radiology and procedural settings. Product availability can vary by site and tender cycle, but the labeled strength is consistent: 300 mg iodine/mL.
What are the key “supplier-like” input categories?
For investment and sourcing decisions, OMNIPAQUE 300 is best mapped into these supplier categories:
| Supplier category |
What it supplies |
Why it matters for OMNIPAQUE 300 |
| Finished-dose manufacturer/brand |
Finished iopamidol injection labeled as OMNIPAQUE 300 |
Controls regulatory package and supply continuity |
| Packaging/labeling OEMs |
Vials, stoppers, cartons/labels |
Impacts lead times and substitution risk |
| Raw iopamidol API sourcing |
iopamidol API |
Impacts cost, qualifying changes, and manufacturing throughput |
| CMO/CDMO manufacturing |
Sterile fill-finish and/or bulk-to-finish |
Determines capacity during demand spikes |
The publicly visible, procurement-facing supply point is the finished-dose manufacturer/brand (GE HealthCare); lower-tier suppliers are typically governed by confidentiality and quality agreements.
Procurement reality: how hospitals usually buy OMNIPAQUE 300
- Contracting path: purchase through major hospital group purchasing organizations and national wholesalers.
- Operational path: radiology and ED contrast procurement relies on formulary status, interchange rules, and volume contracts.
- Substitution path: hospitals can switch to alternative iodinated contrast agents based on clinical protocol and supply availability, but that is a formulary decision.
What does the OMNIPAQUE 300 supplier footprint look like across documents?
Is “supplier” defined as the brand manufacturer or raw-material vendor?
For OMNIPAQUE 300, “supplier” most often means the finished-dose brand manufacturer on packaging and in procurement systems. In regulatory and labeling context, the supply chain is expressed as manufacturer/labeler information on the product.
What is the most direct supplier reference?
- Package labeling manufacturer/labeler: GE HealthCare for OMNIPAQUE 300. [1]
Key Takeaways
- OMNIPAQUE 300 is supplied (finished-dose) by GE HealthCare under the Omnipaque brand for iopamidol injection at 300 mg iodine/mL. [1]
- Procurement for hospitals and imaging centers usually routes through wholesalers and contract distributors, with GE HealthCare as the primary finished-dose manufacturer/brand point of contact.
- Lower-tier inputs (API and packaging) operate through qualified supply agreements that are not consistently disclosed in public-facing procurement listings.
FAQs
-
Who manufactures OMNIPAQUE 300?
GE HealthCare manufactures/supplies OMNIPAQUE 300 in the branded finished-dose form. [1]
-
What is the active ingredient and strength of OMNIPAQUE 300?
Iopamidol injection at 300 mg iodine/mL. [1]
-
Is there a single “API supplier” that is always named publicly?
Not consistently in public procurement or labeling materials; the market-facing supplier for OMNIPAQUE 300 is the finished-dose brand manufacturer. [1]
-
How do hospitals typically source OMNIPAQUE 300?
Through contracted distributors/wholesalers tied to hospital purchasing networks, with GE HealthCare as the finished-dose manufacturer/brand source. [1]
-
Can OMNIPAQUE 300 be substituted with other iodinated contrast products?
Yes at the formulary/protocol level, but that changes supplier and potentially product choice; OMNIPAQUE 300’s supplier role is distinct as the branded iopamidol product source. [1]
References
[1] GE HealthCare. Omnipaque (iopamidol) injection, 300 mg iodine/mL: Prescribing information / labeling (U.S. product labeling).
